The company is a specialty pharmaceutical company engaged in addressing medication abuse and misuse through three proprietary technology platforms. Acura has licensed its technologies to partners including Abuse Deterrent Pharmaceuticals LLC, Zyla Life Sciences, and MainPointe Pharmaceuticals LLC for commercial development.
Cyborg Score Rationale
Acura operates in a niche, high-value market addressing opioid abuse through proprietary technologies, but faces limited scale (11-50 employees) and operates primarily through licensing agreements rather than direct commercialization. The company's dependency on partners and OTC listing reflect limited market prominence.
Top Insights
The company owns three proprietary technology platforms (LIMITX, AVERSION, IMPEDE) addressing different aspects of medication abuse and misuse
Revenue generation appears modest at approximately $1.56 million based on recent financial data
Strategic focus on licensing intellectual property to larger pharmaceutical partners rather than direct commercialization
Products address both opioid abuse (Oxaydo via AVERSION technology) and methamphetamine production (Nexafed via IMPEDE technology)
Named Competitors
Duragesic — Fentanyl patch with abuse-deterrent formulation
OxyContin — Extended-release oxycodone with tamper-resistant formulation
Morphabond — Extended-release morphine with abuse-deterrent features
Open the full interactive Acura Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.